StockWatch
·

BCC FUBA INDIA LTD. Q2 FY27 Results

BCCFUBAQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Broad based#Margin expansion#Record quarter
MetricValue (₹ Cr)vs Q1 FY27
Revenue29.5817.1%
Total Income29.9618.0%
Expenditure24.7421.9%
PBT5.222.6%
Net Profit3.620.0%
OPM19.64%3.70pp
NPM12.08%2.17pp
EPS1.952.0%
View full financials

Revenue grew 73.9% YoY with PAT growing even faster at 150%, driven by genuine operating margin expansion (19.6% vs 15.4% OPM) rather than one-off items, marking this a standout quarter for the core business.

Q2 FY-2027 RESULTS · BCCFUBA

BCC Fuba Q2 FY27: consolidated PAT up 150% YoY to ₹3.62 Cr on margin gains, flat QoQ

PAT +150% YoY · revenue +73.9% · margins expanding

06 Nov 2026 · 3 min read
Revenue

₹29.58 Cr

+73.9% YoY

PAT (consolidated)

₹3.62 Cr

+150% YoY

Net margin

12.08%

+3.6pp YoY

EPS

₹1.95

BCC Fuba India's consolidated revenue rose 73.9% year-on-year to ₹29.58 Cr in Q2 FY27 (vs ₹17.01 Cr in Q2 FY26), and consolidated PAT climbed 150% YoY to ₹3.62 Cr (vs ₹1.45 Cr) — profit growth running well ahead of the topline, the hallmark of genuine margin expansion rather than a one-off. Sequentially both lines were nearly flat: revenue was up 17.1% QoQ over Q1 FY27's ₹25.27 Cr, but PAT was effectively unchanged (₹3.62 Cr vs ₹3.62 Cr) because Q1 had already booked a ₹1.67 Cr one-time catch-up from finalised customer price revisions that inflated that quarter's margins — matching that elevated base without a repeat windfall is the more telling read than the flat headline. Standalone PAT was higher at ₹4.14 Cr (up 186% YoY, EPS ₹2.08 vs consolidated ₹1.95); the gap versus consolidated is entirely the EMS subsidiary IOGEMS Technologies' ₹0.52 Cr quarterly segment loss (₹0.76 Cr for the half).

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹29.58 Cr+17.1%+73.9%
Expenses₹24.74 Cr+21.9%+65.1%
PAT₹3.62 Cr+0.04%+150%
Net margin12.08%-2.2pp+3.6pp
EPS₹1.95-2%+105.3%

Margins expanded on a YoY basis — operating margin (EBITDA/revenue) rose to 19.6% from 15.4% a year ago, and net margin to 12.1% from 8.5% — but both compressed from Q1's 23.3%/14.3% for the reason above. Neither quarter carried exceptional items, so the YoY improvement is operating, not accounting. There is no formal management guidance or outlook on record, and no analyst/brokerage coverage was found for this microcap (searched Nov 2026), so vsGuidance and vsStreet are both unknown rather than estimated. The quarter's other context is a capacity build: consolidated PP&E rose to ₹33.10 Cr from ₹22.57 Cr at March-end, with ₹4.71 Cr of capital work-in-progress, funded by a ₹17.04 Cr share issue during the half (paid-up capital rose to ₹19.89 Cr); the subsidiary separately raised ₹5 Cr via OCDs on Aug 20 to fund its own ramp. Corporate actions this quarter — partly-paid shares converted to fully paid, trading-window closure ahead of results, and a board-approved executive pay revision — were procedural with no earnings impact. Going into Q3, the growth and margin-expansion story is real and YoY-driven, but the Q1 price-revision catch-up means this quarter's flat QoQ print is not a slowdown signal — the cleaner read on run-rate comes once comparisons normalise past Q1's one-off.

₹
168.25209.58250.9292.22333.5528808-0308-2509-1710-1211-0411-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹288, down 4.8% over the past month of trading.

₹ Cr
01.352.74.051.32Q1 FY26rev ₹15 Cr1.45Q2 FY26rev ₹17 Cr1.17Q3 FY26rev ₹17 Cr1.83Q4 FY26rev ₹23 Cr3.62Q1 FY27rev ₹25 Cr3.62Q2 FY27rev ₹30 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

  • W1

    Whether IOGEMS (EMS subsidiary) narrows its loss — ₹0.52 Cr this quarter, ₹0.76 Cr for H1 FY27 — now that it has ₹5 Cr of fresh OCD funding.

  • W2

    Whether the ~₹29-30 Cr quarterly revenue run-rate holds without a repeat of Q1's ₹1.67 Cr one-time price-revision catch-up — Q3 FY27 is the cleaner read on organic growth.

  • W3

    EMS segment revenue is still tiny (₹0.16 Cr this quarter vs ₹29.42 Cr for PCBs) despite the subsidiary absorbing losses and ₹5 Cr of OCD capital — watch whether it scales in coming quarters to justify the funding.

Informational and educational content only. Not investment advice.